Intech Biopharm has finished Phase II clinical trials of new drug SYN006. It is expected to get more than 100M USD for the international licensing-out.

2015/02/03

Intech builds a valuable respiratory specialty pharma and rushes for annual production value of 10 billion NTD.

2014/12/25

Intech Biopharm starts to build the R&D and manufacturing facility of dry powder inhaler(DPI).

2014/12/03

Intech Biopharm gets the approval of US patent application No 13/876,387 for the invention ”Compound composition for Inhalation used for Treating Asthma”.

2014/09/18

Intech Biopharm board meeting makes a resolution to pay 928M NTD and acquire the property of a plant in Hsin Chu Industrial Park for the purpose of inhalers capacity.

2014/07/31

Intech Biopharm goes to list on Emerging Stock Market of Taiwan on June 15, 2014.

2014/07/15

Intech Biopharm’s application report was approved by the Financial Supervisory Commission and its initial public offerings took effect afterwards. Implementation of application affairs will be dealt with, in accordance with relevant regulations.

2014/06/04

Alliance of four domestic major pharmaceutical enterprises leading the project. New domestic anticancer drugs「DCBCI0901」receiving clinical trials

2014/04/22

The new compound drug Synbitide, developed by Intech Biopharm, has achieved the patent of「inhaled compound drug against asthma」 in China, Patent No.201010502339.3. Patents in Taiwan, Japan, the US and other European countries are still under approval.

2014/04/02